United States

Back to map

Showing 81-90 of 356 grants

Title Institution Researcher Program Duration Total Award Amount
Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy Icahn School of Medicine at Mount Sinai Peng Wang Cures 01-July-2025 to 31-December-2026 $305,000.00
Targeting pathogenic Th17 cells as shared mechanisms in MS, SLE and T1D Icahn School of Medicine at Mount Sinai Ka Lung Cheung Cures 01-September-2026 to 31-August-2027 $149,950.03
Exploring the Effects of Beta Cell Regenerative Drugs on Cell Fate Decisions in Human Pancreatic Islets Icahn School of Medicine at Mount Sinai Esra Karakose Cures 01-March-2025 to 28-February-2030 $999,999.00
Bringing Beta Cell Regenerative Therapy to the Clinic Icahn School of Medicine at Mount Sinai Andrew Stewart Cures 01-January-2024 to 31-December-2026 $1,000,000.00
A multiorgan autoimmune T-cell killing in-vitro platform to improve T1D drug screening Indiana Biosciences Research Institute Roberto Mallone Cures 01-June-2026 to 31-May-2027 $196,040.47
Exploiting SDF2L1 to protect against beta cell death and dysfunction in T1D Indiana Biosciences Research Institute Michael Kalwat Cures 01-December-2024 to 30-November-2027 $748,169.00
Clinical Translation of T-1123, an Ultra-rapid, Concentrated, Temperature stable Novel Insulin Analog Invictus Therapeutics, LLC Robyn Day Improving Lives 15-October-2025 to 31-May-2027 $1,437,112.00
Adult T1D Detection at Geisinger IQVIA, Inc. Nadejda Leavitt Cures 01-July-2023 to 30-June-2027 $1,033,123.00
Advancing T1D Detection and Care Through AI IQVIA, Inc. Nadejda Leavitt Cures 01-February-2025 to 31-October-2026 $345,083.00
Advanced Preclinical Development of iTOL-101, a Combination Investigational Product Composed of A Biotechnology-Derived Chimeric Streptavidin and A Fas Ligand (SA-FasL) Protein Bound to Biotinylated Hydrogel-Based Microparticles (Microgel) and Mixed with Deceased Donor Human Pancreatic Islets for the Treatment of Poorly-Controlled (or “Brittle”) Type 1 Diabetes iTolerance, Inc. Camillo Ricordi Cures 01-June-2022 to 31-March-2027 $850,000.00